Pfizer aims to recapture some of the goodwill it gained from rolling out its best-selling Covid-19 vaccine three years ago by putting the “Pfizer for All” brand on a direct-to-consumer medicines platform.
The New York-based drugmaker filed a trademark application in mid-April for a website and app providing medical information as well as mail-order pharmacy and telehealth services to US patients under the brand “Pfizer for All”, according to a US Patent and Trademark Office filing.
The early-stage plans are the latest effort by a pharmaceutical company to circumvent industry middlemen and sell drugs directly to US patients. Earlier this year, weight loss drugmaker Eli Lilly launched its LillyDirect platform in an industry first.
您已阅读21%（739字），剩余79%（2825字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。